Hyperthyroidism Medical Services in China

Hyperthyroidism is a common endocrine disorder characterized by excessive production and secretion of thyroid hormones—primarily thyroxine (T4) and triiodothyronine (T3)—by the thyroid gland. This hormonal surplus accelerates metabolic processes systemically, leading to a constellation of clinical manifestations including unintentional weight loss, palpitations, heat intolerance, tremors, anxiety, insomnia, fatigue, muscle weakness, and menstrual irregularities. The most frequent cause is Graves’ disease—an autoimmune condition in which autoantibodies (TSH receptor antibodies, or TRAb) stimulate the thyroid-stimulating hormone (TSH) receptor, resulting in unregulated hormone synthesis and glandular hyperplasia. Other etiologies include toxic multinodular goiter, solitary toxic adenoma, thyroiditis-induced hormone leakage (e.g., subacute or painless thyroiditis), and exogenous iodine or thyroid hormone intake. Epidemiologically, hyperthyroidism affects approximately 1–2% of the global population, with a striking female predominance (female-to-male ratio ~5–10:1). Incidence peaks between ages 20 and 50, though it can occur at any age—including pediatric and geriatric populations. Risk factors include personal or family history of autoimmune disease (e.g., type 1 diabetes, rheumatoid arthritis, vitiligo), iodine excess (especially in susceptible individuals), smoking (a well-established modifiable risk factor for Graves’ disease and orbitopathy), stress, pregnancy/postpartum period, and certain genetic polymorphisms (e.g., HLA-DR3, CTLA-4). Untreated or poorly controlled hyperthyroidism significantly impairs quality of life: patients often report profound emotional lability, cognitive fog, reduced work productivity, social withdrawal, and sexual dysfunction. Cardiovascular complications—including atrial fibrillation, high-output heart failure, and accelerated osteoporosis—are major contributors to long-term morbidity and mortality. Early diagnosis via sensitive TSH assay, free T4/T3 measurement, and TRAb testing—alongside thyroid ultrasound and radioiodine uptake scanning when indicated—is critical. Without timely intervention, chronic hypermetabolism may precipitate thyroid storm, a rare but life-threatening endocrine emergency with mortality rates exceeding 20%. Management goals are to normalize thyroid hormone levels, alleviate symptoms, prevent complications, and address underlying pathophysiology—while preserving thyroid function where appropriate and minimizing treatment-related side effects.

Hyperthyroidism, characterized by excessive production and secretion of thyroid hormones (primarily thyroxine [T4] and triiodothyronine [T3]), results in a hypermetabolic state affecting multiple organ systems. Common etiologies include Graves’ disease (autoimmune), toxic multinodular goiter, and solitary toxic adenoma. Diagnosis relies on suppressed serum TSH, elevated free T4 and/or free T3, and supportive findings such as positive TSH receptor antibodies (TRAb), radioactive iodine uptake (RAIU) scan, or thyroid ultrasound with Doppler demonstrating increased vascularity. Management is individualized based on etiology, severity, age, comorbidities, pregnancy status, and patient preference.

Conservative treatment serves as the initial cornerstone for most patients—particularly those with mild disease, elderly individuals, or those with contraindications to definitive therapy. It emphasizes symptom control and close clinical monitoring without altering the underlying thyroid pathology. Beta-adrenergic blockers—most commonly propranolol (10–40 mg orally three to four times daily) or atenolol (25–50 mg once daily)—are first-line for rapid alleviation of adrenergic symptoms: tachycardia, palpitations, tremor, anxiety, and heat intolerance. Propranolol additionally inhibits peripheral conversion of T4 to T3, offering added benefit in severe thyrotoxicosis. Nonselective beta-blockers should be avoided in patients with asthma or decompensated heart failure; cardioselective agents like atenolol or bisoprolol are preferred alternatives. Symptomatic management also includes nutritional support (adequate caloric intake with calcium/vitamin D supplementation due to bone turnover acceleration), avoidance of iodine-rich foods or supplements (e.g., kelp, contrast media), and regular ophthalmologic evaluation in Graves’ disease to detect early thyroid eye disease (TED).

Pharmacologic therapy remains the primary nonsurgical intervention for sustained control. Antithyroid drugs (ATDs) inhibit thyroid hormone synthesis via blockade of thyroid peroxidase. Methimazole (MMI) is preferred in nonpregnant adults due to its once- or twice-daily dosing (starting dose 10–30 mg/day), longer half-life, and superior efficacy compared to propylthiouracil (PTU). PTU (starting dose 50–150 mg/day in divided doses) is reserved for first-trimester pregnancy, thyroid storm, or MMI intolerance due to its lower placental transfer and ability to inhibit peripheral T4-to-T3 conversion. Treatment follows a titration regimen (adjusting dose to maintain euthyroidism) or block-replace strategy (high-dose ATD plus levothyroxine), though the latter is rarely used today due to complexity and lack of outcome advantage. Duration is typically 12–18 months; approximately 40–50% of Graves’ patients achieve durable remission after discontinuation. Key adverse effects include agranulocytosis (<0.3%), hepatitis, vasculitis, and rash—mandating prompt cessation and urgent evaluation for fever, sore throat, or jaundice. Liver function tests and complete blood counts are recommended at baseline and periodically during therapy.

Surgical treatment—total or near-total thyroidectomy—is indicated for large compressive goiters, suspected malignancy, severe TED unresponsive to immunosuppression, ATD intolerance or failure, or patient preference for definitive therapy. Preoperative preparation is critical: patients must be rendered euthyroid using ATDs, followed by potassium iodide (Lugol’s solution, 5–10 drops twice daily for 7–10 days) to reduce gland vascularity and intraoperative bleeding. Beta-blockade is continued perioperatively. Surgery is performed by high-volume endocrine surgeons using nerve monitoring to preserve the recurrent laryngeal nerves and parathyroid glands. Complication rates in experienced centers are low: permanent hypoparathyroidism (1–2%), recurrent laryngeal nerve injury (<1%), and postoperative hematoma (<0.5%). Lifelong levothyroxine replacement is required after total thyroidectomy. Radioactive iodine (RAI, I-131) is not classified as surgical but is a definitive ablative modality widely used in China and globally; however, it is contraindicated in pregnancy, lactation, and uncontrolled active TED. RAI is generally avoided in children and young adults in China due to regulatory preferences and patient concerns about radiation exposure.

Treatment advantages in China reflect integration of advanced diagnostics, standardized protocols, and multidisciplinary coordination within endocrinology departments. Major tertiary hospitals employ high-resolution thyroid ultrasound with elastography and AI-assisted nodule characterization, enabling precise risk stratification. RAI therapy is administered under strict national radiation safety regulations, with dedicated nuclear medicine units ensuring accurate dosimetry and follow-up. Chinese guidelines emphasize early TRAb quantification to predict relapse risk and guide duration of ATD therapy. Moreover, China has pioneered cost-effective generic ATDs with stringent bioequivalence standards, improving accessibility. Integrated care models link endocrinologists, thyroid surgeons, nuclear medicine specialists, ophthalmologists, and nutritionists—particularly beneficial for complex Graves’ cases with TED or cardiovascular complications. Telemedicine platforms facilitate longitudinal monitoring in rural regions, reducing disparities in access to specialist care.

Recovery advice focuses on long-term health maintenance and complication prevention. Patients completing ATD therapy require lifelong annual TSH/free T4 screening to detect recurrence or subsequent hypothyroidism. Post-thyroidectomy or post-RAI patients need lifelong thyroid hormone replacement with levothyroxine, taken on an empty stomach 30–60 minutes before breakfast, avoiding calcium, iron, or proton-pump inhibitors within four hours. Serum TSH should be monitored every 6–8 weeks until stable, then annually. Bone health is paramount: dual-energy X-ray absorptiometry (DEXA) scanning is advised for postmenopausal women and men >65 years with prolonged thyrotoxicosis history; calcium (1200 mg/day) and vitamin D (800–2000 IU/day) supplementation is routine. Cardiovascular surveillance—including ECG and echocardiography in patients with persistent tachycardia or atrial fibrillation—is essential. Psychological support is encouraged, as anxiety and mood lability may persist despite biochemical control. Patients with Graves’ ophthalmopathy should avoid smoking absolutely (a major exacerbating factor), use lubricating eye drops, wear UV-protective sunglasses, and seek prompt ophthalmology referral for diplopia, vision changes, or orbital pain. Finally, all patients should carry medical identification indicating thyroid disorder status and current therapy, especially prior to elective procedures or imaging involving iodinated contrast.